Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

Leukemia

Volumn 26, Issue 12, 2012, Pages 2538-2545

  Kim, D ^a   Wang, J ^a,b   Willingham, S B ^a   Martin, R ^a   Wernig, G ^a   Weissman, I L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

CD47; multiple myeloma; myeloma initiating cells; therapeutic antibody; xenotransplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CD38 ANTIGEN; CD45 ANTIGEN; CD47 ANTIGEN; CD47 ANTIGEN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; MACROPHAGE; MOUSE; MYELOMA; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; OSTEOLYSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD47; BONE AND BONES; DNA-BINDING PROTEINS; FEMALE; FETUS; FLOW CYTOMETRY; HUMANS; MACROPHAGES; MICE; MULTIPLE MYELOMA; PHAGOCYTOSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84871182464     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.141     Document Type: Article

References (40)

1. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908-2913.
2. Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008; 112: 2935-2945.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
4. Rajkumar SV. Treatment of relapsed or refractory multiple myeloma. In: Kyle RA, Basow DS (eds) UpToDate. UpToDate: Waltham, MA, 2010.
5. Mawby WJ, Holmes CH, Anstee DJ, Spring FA, Tanner MJ. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J 1994; 304(Pt 2): 525-530.
6. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000; 288: 2051-2054.
7. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193: 855-862.
8. Lagadec P, Dejoux O, Ticchioni M, Cottrez F, Johansen M, Brown EJ et al. Involvement of a CD47-dependent pathway in platelet adhesion on inflamed vascular endothelium under flow. Blood 2003; 101: 4836-4843.
9. Gresham HD, Goodwin JL, Allen PM, Anderson DC, Brown EJ. A novel member of the integrin receptor family mediates Arg-Gly-Asp-stimulated neutrophil phagocytosis. J Cell Biol 1989; 108: 1935-1943.
10. Brown E, Hooper L, Ho T, Gresham H. Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol 1990; 111(6 Pt 1): 2785-2794.
11. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138: 271-285.
12. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-299.
13. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142: 699-713.
14. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011; 118: 4890-4901.
15. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 14016-14021.
16. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012; 109: 6662-6667.
17. Campbell IG, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmem-brane domains. Cancer Res 1992; 52: 5416-5420.
18. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757.
19. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
20. Namikawa R, Ueda R, Kyoizumi S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 1993; 82: 2526-2536.
21. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med 2005; 113: 183-190.
22. Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 2007; 127: 176-181.
23. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
24. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45low/-CD38high/CD138\+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia (in press).
25. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011; 71: 1374-1384.
26. Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y et al. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed anti-tumor potency for multiple myeloma. Leuk Res 2005; 29: 445-450.
27. de Bruijn MF, Slieker WA, van der Loo JC, Voerman JS, van Ewijk W, Leenen PJ. Distinct mouse bone marrow macrophage precursors identified by differential expression of ER-MP12 and ER-MP20 antigens. Eur J Immunol 1994; 24: 2279-2284.
28. Yamao T, Noguchi T, Takeuchi O, Nishiyama U, Morita H, Hagiwara T et al. Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem 2002; 277: 39833-39839.
29. Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 2005; 174: 2004-2011.
30. Ide K, Wang H, Tahara H, Liu J, Wang X, Asahara T et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci USA 2007; 104: 5062-5066.
31. Kikuchi Y, Uno S, Yoshimura Y, Otabe K, Iida S, Oheda M et al. A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells. Biochem Biophys Res Commun 2004; 315: 912-918.
32. Johansson U, Higginbottom K, Londei M. CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand J Immunol 2004; 59: 40-49.
33. Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Iizuka K et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lympho-hematopoietic cells. J Exp Med 2001; 194: 541-549.
34. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346-351.
35. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986-991.
36. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 2003; 4: 310-314.
37. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993; 90: 2060-2064.
38. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
39. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175-1182.
40. Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009; 114: 3413-3421.